Health · 53 views
Subcutaneous tarlatamab shows favorable safety profile and antitumor activity in extensive-stage small cell lung cancer
Subcutaneous administration of tarlatamab was well tolerated and demonstrated preliminary antitumor activity in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC), according to findings from the phase 1b…
Summary
Subcutaneous administration of tarlatamab was well tolerated and demonstrated preliminary antitumor activity in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC), according to findings from the phase 1b DeLLphi-308 study presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer ( WCLC ). Tarlatamab is a bispecific T-cell engager (BiTE) immunotherapy with established clinical activity in small cell lung cancer and has previously been evaluated using intravenous administration.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Hereditary lung and liver disease successfully treated for the first time using gene correctionContinue reading
- Washington state resident dies from bird flu following exposure to infected cattleContinue reading
- Study shows AI may improve patient discharge summariesContinue reading
- Postop morbidity lower with laparoscopic versus open resection of colorectal liver metastasesContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow